What a new study presented at the American Society of Clinical Oncology (ASCO) World Congress reveals
The REA Clinic received international recognition at the World Congress of the American Society of Clinical Oncology (ASCO). It is the most important conference for Oncology, at a global level.
At the conference, a pioneering study was presented for the first time with the object of investigating the molecular biomarkers p53 & MMR, which are particularly important prognostic and therapeutic factors in endometrial cancer (the publication of the study: https://meetings.asco.org/abstracts- presentations/237682).
It is worth noting that endometrial cancer is the most common malignancy of the female reproductive system in developed countries and is responsible for 97,700 deaths worldwide every year. Both incidence and mortality have been increasing in recent years. It occurs in the endometrium, i.e. the tissue that covers the uterine cavity, mainly after menopause. In the majority of cases it is diagnosed at an early stage, resulting in very high cure rates.
The pioneering study
The study conducted by the specialized research team of the REA Clinic evaluated the concordance of the results of oncoprotein p53 and DNA repair genes (MMR), through immunohistochemistry, between hysteroscopy and hysterectomy samples, in patients with early endometrial cancer .
Protein 53 (p53) has been described as the “guardian of the genome”, as it has the ability to neutralize cancer cells and protect healthy cells, thereby suppressing cancer. The greater the “damage”, the more active the gene is, leading researchers to define p53 levels as a risk marker for DNA damage.
Results showed absolute agreement (100%) for p53 and 98.96% agreement for MMR genes!
These findings suggest that assessment of p53 and MMR biomarkers – in hysteroscopy specimens – is as reliable as assessment in hysterectomy specimens.
This conclusion is particularly important as knowledge of the molecular status of endometrial cancer before surgery can guide decisions regarding its surgical treatment, but also fertility preservation options, making it unnecessary to re-evaluate specific biomarkers after hysterectomy. . Also, another important element, according to the researchers, is that the cost of treatment is reduced.
The president of the REA Clinic, Mr. Mitsakos-Barbagiannis Kyriakos, stated that “this distinction confirms the commitment of the REA Clinic to innovation and excellence in the field of gynecological oncology, but also in general to the provision of top healthcare, contributing to the development of innovative therapeutics approaches that can improve patients’ lives.”
Source :Skai
I have worked in the news industry for over 10 years. I have a vast amount of experience in covering health news. I am also an author at News Bulletin 247. I am highly experienced and knowledgeable in this field. I am a hard worker and always deliver quality work. I am a reliable source of information and always provide accurate information.
